On February 3, 2020 BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") reported, that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission (the "SEC") to offer 6,000,000 American Depositary Shares ("ADSs") representing its ordinary shares (Press release, BioNTech, FEB 3, 2020, View Source [SID1234553769]). In addition, BioNTech intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 of ADSs in connection with the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BioNTech is a clinical-stage biopharmaceutical company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan, BofA Securities, Berenberg and SVB Leerink are acting as lead joint book-running managers for the offering.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the preliminary prospectus, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at +1 (866) 803-9204, or by e-mail at [email protected]; BofA Securities, Inc., NC1-004-03-43; 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by e-mail at [email protected]; Berenberg Capital Markets LLC, Attention: Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, New York 10020, or by telephone at +1 (646) 949-9000, or by e-mail at [email protected]; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by telephone at +1 (800) 808-7525, ext. 6132, or by e-mail at [email protected].

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

On February 3, 2020 Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, reported the acceptance of an abstract for presentation at the ASCO (Free ASCO Whitepaper)-SITC Clinical Immuno-Oncology Symposium, which is being held February 6 to February 8, 2020, at the Rosen Shingle Creek Resort in Orlando, Florida (Press release, Calidi Biotherapeutics, FEB 3, 2020, View Source [SID1234553786]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing our data evidencing the ability of Calidi’s proprietary cell-based delivery platform to address a major obstacle in oncolytic virotherapy – the quick elimination of oncolytic viruses by the patient’s immune system," said Boris Minev, MD, President, Medical and Scientific Affairs, Calidi Biotherapeutics. "Calidi’s platform not only protects, amplifies, and delivers the oncolytic viruses, but it also modifies the tumor microenvironment and activates the immune system to actively seek, and destroy distant tumor sites."

ASCO-SITC Presentation Details Are As Follows:

Board C3
Abstract 21: A cell-based platform to potentiate oncolytic virus therapies.

Date: Thursday, February 6, from 11:30 AM – 1:00 PM and 6:00 PM – 7:00 PM
Location: Rosen Shingle Creek, Orlando, FL
Key Words: oncolytic virus, cancer, cancer therapies, cell-based delivery platform

On February 2, 2020 Children’s Hospital Los Angeles (CHLA) reported that the Margie and Robert E. Petersen Foundation has contributed $25 million to establish an endowment supporting three of the hospital’s signature programs: the Cancer and Blood Disease Institute (CBDI), the Vision Center and Inpatient Rehabilitation Services (Press release, Children’s Hospital Los Angeles, FEB 2, 2020, View Source [SID1234553750]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This endowment expands the Petersen’s legacy of generosity by providing CHLA with a resource that will forever advance our mission to create hope and build healthier futures for children," says President and CEO Paul S. Viviano. "I am so grateful for this gift that will support a wide range of initiatives including research projects, technology upgrades, clinical care, key physician recruitment, capital projects, unreimbursed care and more."

The Margie and Robert E. Petersen Foundation, led by President GiGi Carleton, supports children’s health and well-being throughout Southern California, fulfilling the Petersen’s desire to care for the community by helping all children reach their full potential. Margie Petersen was a former CHLA Trustee, and both she and her husband Robert Petersen, founder and chairman of Petersen Publishing Co., were longtime supporters of the hospital. The Foundation has supported several CHLA programs and projects over the years, including an $8.5 million gift to open a state-of-the-art inpatient rehabilitation space in 2015, named the Margie and Robert E. Petersen Foundation Rehabilitation Center and honoring their sons Bobby and Richie Petersen.

"Through their transformative philanthropy and leadership, the Petersens dedicated their lives to helping children overcome obstacles of all kinds," says Alexandra Carter, CHLA Senior Vice President and Chief Development Officer. "They would be proud to know that this gift will help save children from debilitating illnesses by helping one of the nation’s top children’s hospitals provide families and patients the multidisciplinary, family-centered care they need."

In recognition of this transformative gift, CHLA will be naming the main driveway at its 4650 Sunset Boulevard campus the Margie and Robert E. Petersen Entry Plaza, in honor of Mr. Petersen’s role as founding publisher of Hot Rod and Motor Trend magazines and founder of the Petersen Automotive Museum.

On February 1, 2020 Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, reported that updated results from its Phase 1/1b clinical trial of CPI-818, the Company’s ITK-inhibitor, which were presented in an oral presentation at the 12th Annual T-Cell Lymphoma Forum in La Jolla, California, taking place January 30 to February 1, 2020 (Press release, Corvus Pharmaceuticals, FEB 1, 2020, View Source [SID1234553771]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our Phase 1/1b clinical trial of CPI-818, our selective covalent ITK inhibitor designed to address T-cell lymphomas, is enrolling well and continues to provide promising clinical data for patients with advanced, refractory forms of this cancer," said Mehrdad Mobasher, M.D., chief medical officer of Corvus. "To-date, the data demonstrates that the biology and pharmacology of ITK inhibition with CPI-818 has been as expected and the trial is proceeding according to plan. We are pleased to provide this update at the T-Cell Lymphoma Forum, a meeting dedicated to this difficult to treat family of cancers. We are now ready to advance the trial to higher drug doses where we will evaluate its activity in specific disease cohorts."

The CPI-818 Phase 1/1b study is currently enrolling patients with several types of advanced, refractory T-cell lymphomas, including peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), cutaneous T-cell lymphoma (CTCL) and other T-cell lymphomas. The study employs an adaptive, expansion cohort design to select the dose and evaluate the safety, pharmacokinetics (PK), target occupancy, biomarkers and efficacy of CPI-818. The initial phase of the trial is evaluating escalating doses in successive cohorts of patients in order to determine the optimum dose. A second phase will evaluate safety and tumor response to this optimum dose of CPI-818 in disease-specific patient cohorts that may be expanded based on early signs of efficacy. The study is enrolling patients at major medical centers in the United States, Australia and South Korea.

CPI-818 Phase 1/1b Clinical Trial Results at 12th Annual T-Cell Lymphoma Forum
The preclinical and early clinical data from the Phase 1/1b clinical trial of CPI-818 were presented by Dr. Mobasher in an oral presentation session at the T-Cell Lymphoma Forum. The data builds on preclinical and early clinical data from the first seven patients in the study presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) 61st Annual Meeting, which took place in December 2019. The key updates from Dr. Mobasher’s presentation, which is titled "CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor. Pre-clinical Characterization and Interim Results of a Phase I/Ib Dose-Escalation Trial in Patients with Relapsed/Refractory T-Cell Lymphoma," included:

16 patients have been enrolled in the first four dose cohorts in the initial phase of the trial, receiving a 100 mg, 200 mg, 400 mg or 600 mg oral dose of CPI-818 two times per day, with no dose limiting toxicities and no grade 3 or 4 treatment related adverse events observed.
The median patient follow-up period is now three months, with 11 patients remaining on therapy. One patient with CTCL treated with the 200 mg dose of CPI-818 achieved a reduction in lymphadenopathy and improvement of PET scan imaging; another patient with CTCL receiving the 400 mg dose has exhibited improvement in cutaneous disease. These patients continue on therapy.
The results from the pharmacokinetic and occupancy studies for the first 12 patients have been in-line with expectations, with increasing target occupancy with higher doses based on available data from the 100 mg, 200 mg, and 400 mg doses. The maximum target occupancy has not yet been achieved in the first three dose cohorts, but the Company continues to anticipate that maximum target occupancy will be achieved in the 600 mg cohort, which was recently initiated.

On January 31, 2020 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reported that it will announce its final results for the year ended December 31, 2019 on Tuesday, March 3, 2020 at 7:00 am Greenwich Mean Time (GMT) (Press release, Hutchison China MediTech, JAN 31, 2020, https://www.chi-med.com/chi-med-to-announce-2019-final-results/ [SID1234553733]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A presentation for analysts and investors will be held at 9:00 am GMT (5:00 pm Hong Kong Time) on the same day at Panmure Gordon, One New Change, London, EC4M 9AF, UK. The presentation will be webcast live via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins.

For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Standard Time (2:00 pm GMT on the same day).

Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.